Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity

William Shakespeare, Michael Yang, Regine Bohacek, Franklin Cerasoli, Karin Stebbins, Raji Sundaramoorthi, Mihai Azimioara, Chi Vu, Selvi Pradeepan, Chester Metcalf, Chad Haraldson, Taylor Merry, David Dalgarno, Surinder Narula, Marcos Hatada, Xiaode Lu, Marie Rose Van Schravendijk, Susan Adams, Shelia Violette, Jeremy SmithWei Guan, Catherine Bartlett, Jay Herson, John Iuliucci, Manfred Weigele, Tomi Sawyer

Research output: Contribution to journalArticle

Abstract

Targeted disruption of the pp60(src) (Src) gene has implicated this tyrosine kinase in osteoclast-mediated bone resorption and as a therapeutic target for the treatment of osteoporosis and other bone-related diseases. Herein we describe the discovery of a nonpeptide inhibitor (AP22408) of Src that demonstrates in vivo antiresorptive activity. Based on a cocrystal structure of the noncatalytic Src homology 2 (SH2) domain of Src complexed with citrate [in the phosphotyrosine (pTyr) binding pocket], we designed 3',4'-diphosphonophenylalanine (Dpp) as a pTyr mimic. In addition to its design to bind Src SH2, the Dpp moiety exhibits bone-targeting properties that confer osteoclast selectivity, hence minimizing possible undesired effects on other cells that have Src-dependent activities. The chemical structure AP22408 also illustrates a bicyclic template to replace the post-pTyr sequence of cognate Src SH2 phosphopeptides such as Ac-pTyr-Glu-Glu-Ile (1). An x-ray structure of AP22408 complexed with Lck (S164C) SH2 confirmed molecular interactions of both the Dpp and bicyclic template of AP22408 as predicted from molecular modeling. Relative to the cognate phosphopeptide, AP22408 exhibits significantly increased Src SH2 binding affinity (IC50 = 0.30 μM for AP22408 and 5.5 μM for 1). Furthermore, AP22408 inhibits rabbit osteoclast-mediated resorption of dentine in a cellular assay, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay, and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model.

Original languageEnglish (US)
Pages (from-to)9373-9378
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume97
Issue number17
DOIs
StatePublished - Aug 15 2000
Externally publishedYes

Fingerprint

Osteoclasts
Phosphotyrosine
Phosphopeptides
src Genes
Bone and Bones
src Homology Domains
Bone Diseases
Dentin
Durapatite
Bone Resorption
AP22408
Parathyroid Hormone
Citric Acid
Protein-Tyrosine Kinases
Inhibitory Concentration 50
Adsorption
Osteoporosis
X-Rays
Rabbits

ASJC Scopus subject areas

  • General

Cite this

Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. / Shakespeare, William; Yang, Michael; Bohacek, Regine; Cerasoli, Franklin; Stebbins, Karin; Sundaramoorthi, Raji; Azimioara, Mihai; Vu, Chi; Pradeepan, Selvi; Metcalf, Chester; Haraldson, Chad; Merry, Taylor; Dalgarno, David; Narula, Surinder; Hatada, Marcos; Lu, Xiaode; Van Schravendijk, Marie Rose; Adams, Susan; Violette, Shelia; Smith, Jeremy; Guan, Wei; Bartlett, Catherine; Herson, Jay; Iuliucci, John; Weigele, Manfred; Sawyer, Tomi.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, No. 17, 15.08.2000, p. 9373-9378.

Research output: Contribution to journalArticle

Shakespeare, W, Yang, M, Bohacek, R, Cerasoli, F, Stebbins, K, Sundaramoorthi, R, Azimioara, M, Vu, C, Pradeepan, S, Metcalf, C, Haraldson, C, Merry, T, Dalgarno, D, Narula, S, Hatada, M, Lu, X, Van Schravendijk, MR, Adams, S, Violette, S, Smith, J, Guan, W, Bartlett, C, Herson, J, Iuliucci, J, Weigele, M & Sawyer, T 2000, 'Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity', Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 17, pp. 9373-9378. https://doi.org/10.1073/pnas.97.17.9373
Shakespeare, William ; Yang, Michael ; Bohacek, Regine ; Cerasoli, Franklin ; Stebbins, Karin ; Sundaramoorthi, Raji ; Azimioara, Mihai ; Vu, Chi ; Pradeepan, Selvi ; Metcalf, Chester ; Haraldson, Chad ; Merry, Taylor ; Dalgarno, David ; Narula, Surinder ; Hatada, Marcos ; Lu, Xiaode ; Van Schravendijk, Marie Rose ; Adams, Susan ; Violette, Shelia ; Smith, Jeremy ; Guan, Wei ; Bartlett, Catherine ; Herson, Jay ; Iuliucci, John ; Weigele, Manfred ; Sawyer, Tomi. / Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. In: Proceedings of the National Academy of Sciences of the United States of America. 2000 ; Vol. 97, No. 17. pp. 9373-9378.
@article{255c21fdbe714dd5aabac3adf979ea6f,
title = "Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity",
abstract = "Targeted disruption of the pp60(src) (Src) gene has implicated this tyrosine kinase in osteoclast-mediated bone resorption and as a therapeutic target for the treatment of osteoporosis and other bone-related diseases. Herein we describe the discovery of a nonpeptide inhibitor (AP22408) of Src that demonstrates in vivo antiresorptive activity. Based on a cocrystal structure of the noncatalytic Src homology 2 (SH2) domain of Src complexed with citrate [in the phosphotyrosine (pTyr) binding pocket], we designed 3',4'-diphosphonophenylalanine (Dpp) as a pTyr mimic. In addition to its design to bind Src SH2, the Dpp moiety exhibits bone-targeting properties that confer osteoclast selectivity, hence minimizing possible undesired effects on other cells that have Src-dependent activities. The chemical structure AP22408 also illustrates a bicyclic template to replace the post-pTyr sequence of cognate Src SH2 phosphopeptides such as Ac-pTyr-Glu-Glu-Ile (1). An x-ray structure of AP22408 complexed with Lck (S164C) SH2 confirmed molecular interactions of both the Dpp and bicyclic template of AP22408 as predicted from molecular modeling. Relative to the cognate phosphopeptide, AP22408 exhibits significantly increased Src SH2 binding affinity (IC50 = 0.30 μM for AP22408 and 5.5 μM for 1). Furthermore, AP22408 inhibits rabbit osteoclast-mediated resorption of dentine in a cellular assay, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay, and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model.",
author = "William Shakespeare and Michael Yang and Regine Bohacek and Franklin Cerasoli and Karin Stebbins and Raji Sundaramoorthi and Mihai Azimioara and Chi Vu and Selvi Pradeepan and Chester Metcalf and Chad Haraldson and Taylor Merry and David Dalgarno and Surinder Narula and Marcos Hatada and Xiaode Lu and {Van Schravendijk}, {Marie Rose} and Susan Adams and Shelia Violette and Jeremy Smith and Wei Guan and Catherine Bartlett and Jay Herson and John Iuliucci and Manfred Weigele and Tomi Sawyer",
year = "2000",
month = "8",
day = "15",
doi = "10.1073/pnas.97.17.9373",
language = "English (US)",
volume = "97",
pages = "9373--9378",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "17",

}

TY - JOUR

T1 - Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity

AU - Shakespeare, William

AU - Yang, Michael

AU - Bohacek, Regine

AU - Cerasoli, Franklin

AU - Stebbins, Karin

AU - Sundaramoorthi, Raji

AU - Azimioara, Mihai

AU - Vu, Chi

AU - Pradeepan, Selvi

AU - Metcalf, Chester

AU - Haraldson, Chad

AU - Merry, Taylor

AU - Dalgarno, David

AU - Narula, Surinder

AU - Hatada, Marcos

AU - Lu, Xiaode

AU - Van Schravendijk, Marie Rose

AU - Adams, Susan

AU - Violette, Shelia

AU - Smith, Jeremy

AU - Guan, Wei

AU - Bartlett, Catherine

AU - Herson, Jay

AU - Iuliucci, John

AU - Weigele, Manfred

AU - Sawyer, Tomi

PY - 2000/8/15

Y1 - 2000/8/15

N2 - Targeted disruption of the pp60(src) (Src) gene has implicated this tyrosine kinase in osteoclast-mediated bone resorption and as a therapeutic target for the treatment of osteoporosis and other bone-related diseases. Herein we describe the discovery of a nonpeptide inhibitor (AP22408) of Src that demonstrates in vivo antiresorptive activity. Based on a cocrystal structure of the noncatalytic Src homology 2 (SH2) domain of Src complexed with citrate [in the phosphotyrosine (pTyr) binding pocket], we designed 3',4'-diphosphonophenylalanine (Dpp) as a pTyr mimic. In addition to its design to bind Src SH2, the Dpp moiety exhibits bone-targeting properties that confer osteoclast selectivity, hence minimizing possible undesired effects on other cells that have Src-dependent activities. The chemical structure AP22408 also illustrates a bicyclic template to replace the post-pTyr sequence of cognate Src SH2 phosphopeptides such as Ac-pTyr-Glu-Glu-Ile (1). An x-ray structure of AP22408 complexed with Lck (S164C) SH2 confirmed molecular interactions of both the Dpp and bicyclic template of AP22408 as predicted from molecular modeling. Relative to the cognate phosphopeptide, AP22408 exhibits significantly increased Src SH2 binding affinity (IC50 = 0.30 μM for AP22408 and 5.5 μM for 1). Furthermore, AP22408 inhibits rabbit osteoclast-mediated resorption of dentine in a cellular assay, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay, and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model.

AB - Targeted disruption of the pp60(src) (Src) gene has implicated this tyrosine kinase in osteoclast-mediated bone resorption and as a therapeutic target for the treatment of osteoporosis and other bone-related diseases. Herein we describe the discovery of a nonpeptide inhibitor (AP22408) of Src that demonstrates in vivo antiresorptive activity. Based on a cocrystal structure of the noncatalytic Src homology 2 (SH2) domain of Src complexed with citrate [in the phosphotyrosine (pTyr) binding pocket], we designed 3',4'-diphosphonophenylalanine (Dpp) as a pTyr mimic. In addition to its design to bind Src SH2, the Dpp moiety exhibits bone-targeting properties that confer osteoclast selectivity, hence minimizing possible undesired effects on other cells that have Src-dependent activities. The chemical structure AP22408 also illustrates a bicyclic template to replace the post-pTyr sequence of cognate Src SH2 phosphopeptides such as Ac-pTyr-Glu-Glu-Ile (1). An x-ray structure of AP22408 complexed with Lck (S164C) SH2 confirmed molecular interactions of both the Dpp and bicyclic template of AP22408 as predicted from molecular modeling. Relative to the cognate phosphopeptide, AP22408 exhibits significantly increased Src SH2 binding affinity (IC50 = 0.30 μM for AP22408 and 5.5 μM for 1). Furthermore, AP22408 inhibits rabbit osteoclast-mediated resorption of dentine in a cellular assay, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay, and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model.

UR - http://www.scopus.com/inward/record.url?scp=12944281813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944281813&partnerID=8YFLogxK

U2 - 10.1073/pnas.97.17.9373

DO - 10.1073/pnas.97.17.9373

M3 - Article

C2 - 10944210

AN - SCOPUS:12944281813

VL - 97

SP - 9373

EP - 9378

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 17

ER -